The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1292
Antiplatelet Therapy for Patients with Stents
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The antiplatelet agents aspirin and clopidogrel (Plavix, and others)1 are used in most patients undergoing percutaneous coronary intervention (PCI) to prevent stent thrombosis and to reduce the occurrence of peri-, post-procedural and late cardiovascular events. Despite a large number of randomized trials of these agents in such patients, the optimal dosage and duration of treatment with these drugs, and whether other drugs should be added, is unclear.

BEFORE PCI — Aspirin – The minimal effective dose of aspirin has not been established. The present recommendation in the American College of Cardiology (ACC)/American Heart Association (AHA) Guidelines is to give 75-325 mg of aspirin (81 mg is the lowest dose available in the US) before PCI to patients on chronic aspirin therapy and 300-325 mg of aspirin to patients not on chronic aspirin therapy a minimum of 2 hours before ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Antiplatelet Therapy for Patients with Stents
Article code: 1292a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian